Stifel raises GE HealthCare stock price target to $90 on strong Q3
Stifel raised its price target on GE HealthCare (GEHC) to $90 from $80, citing strong Q3 2026 results. The company reported $5.51B in sales, exceeding estimates, with growth across all segments. GEHC raised its full-year guidance and has a record backlog of $23.7B. InvestingPro analysis suggests the stock is undervalued.
How this was made
The 30-second read
Why it matters
The earnings beat and target raise provide a fresh catalyst, likely prompting buying interest.
Market read
Strong earnings and an analyst upgrade make GEHC a candidate for short‑term bullish positioning.
What to watch
Potential supply‑chain constraints or macro‑economic slowdown could temper growth despite the upbeat report.
Background
The article summarizes GE HealthCare's Q3 2026 earnings, highlights organic growth, segment performance, and Stifel's upgraded price target.
Ticker impact
Stifel raised its price target on GE HealthCare to $90 after the company reported Q3 sales of $5.51B and raised full-year guidance.
likely upward pressure as investors price in the upgraded target and strong earnings.
The price target increase is a fresh, material analyst action following the earnings release, providing a clear catalyst for short‑term buying.
Market effects
Positive for the health‑care equipment sector as earnings beat may lift peers.
U.S. health‑care stocks could see modest gains.
Limited to investors tracking U.S. health‑care equities.
Counterpoint
The target raise may already be priced in; a pullback could occur if guidance falls short of expectations.
Key entities
- companyGE HealthCare
U.S.-listed health‑care equipment and services provider.
- analystStifel
Equity research firm that raised the price target.
